Cargando…
MMP2 as an independent prognostic stratifier in oral cavity cancers
BACKGROUND: Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC, using a biology-driven strategy. PATIENTS AN...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466851/ https://www.ncbi.nlm.nih.gov/pubmed/32934875 http://dx.doi.org/10.1080/2162402X.2020.1754094 |
_version_ | 1783577903049474048 |
---|---|
author | Hoffmann, Caroline Vacher, Sophie Sirven, Philémon Lecerf, Charlotte Massenet, Lucile Moreira, Aurélie Surun, Aurore Schnitzler, Anne Klijanienko, Jerzy Mariani, Odette Jeannot, Emmanuelle Badois, Nathalie Lesnik, Maria Choussy, Olivier Le Tourneau, Christophe Guillot-Delost, Maude Kamal, Maud Bieche, Ivan Soumelis, Vassili |
author_facet | Hoffmann, Caroline Vacher, Sophie Sirven, Philémon Lecerf, Charlotte Massenet, Lucile Moreira, Aurélie Surun, Aurore Schnitzler, Anne Klijanienko, Jerzy Mariani, Odette Jeannot, Emmanuelle Badois, Nathalie Lesnik, Maria Choussy, Olivier Le Tourneau, Christophe Guillot-Delost, Maude Kamal, Maud Bieche, Ivan Soumelis, Vassili |
author_sort | Hoffmann, Caroline |
collection | PubMed |
description | BACKGROUND: Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC, using a biology-driven strategy. PATIENTS AND METHODS: Tumor and juxtatumor secretome were analyzed in a prospective discovery cohort of 37 OCSCC treated by primary surgery. Independent biomarker validation was performed by RTqPCR in a retrospective cohort of 145 patients with similar clinical features. An 18-gene signature (18 G) predictive of the response to PD-1 blockade was evaluated in the same cohort. RESULTS: Among 29 deregulated molecules identified in a secretome analysis, including chemokines, cytokines, growth factors, and molecules related to tumor growth and tissue remodeling, only soluble MMP2 was a prognostic biomarker. In our validation cohort, high levels of MMP2 and CD276, and low levels of CXCL10 and STAT1 mRNA were associated with poor prognosis in univariate analysis (Kaplan-Meier). MMP2 (p = .001) and extra-nodal extension (ENE) (p = .006) were independent biomarkers of disease-specific survival (DSS) in multivariate analysis and defined prognostic groups with 5-year DSS ranging from 36% (MMP2highENE+) to 88% (MMP2lowENE-). The expression of 18 G was similar in the different prognostic groups, suggesting comparable responsiveness to anti-PD-1. CONCLUSION: High levels of MMP2 were an independent and validated prognostic biomarker, surpassing other molecules of a large panel of the tumor and immune-related processes, which may be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens. |
format | Online Article Text |
id | pubmed-7466851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74668512020-09-14 MMP2 as an independent prognostic stratifier in oral cavity cancers Hoffmann, Caroline Vacher, Sophie Sirven, Philémon Lecerf, Charlotte Massenet, Lucile Moreira, Aurélie Surun, Aurore Schnitzler, Anne Klijanienko, Jerzy Mariani, Odette Jeannot, Emmanuelle Badois, Nathalie Lesnik, Maria Choussy, Olivier Le Tourneau, Christophe Guillot-Delost, Maude Kamal, Maud Bieche, Ivan Soumelis, Vassili Oncoimmunology Original Research BACKGROUND: Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC, using a biology-driven strategy. PATIENTS AND METHODS: Tumor and juxtatumor secretome were analyzed in a prospective discovery cohort of 37 OCSCC treated by primary surgery. Independent biomarker validation was performed by RTqPCR in a retrospective cohort of 145 patients with similar clinical features. An 18-gene signature (18 G) predictive of the response to PD-1 blockade was evaluated in the same cohort. RESULTS: Among 29 deregulated molecules identified in a secretome analysis, including chemokines, cytokines, growth factors, and molecules related to tumor growth and tissue remodeling, only soluble MMP2 was a prognostic biomarker. In our validation cohort, high levels of MMP2 and CD276, and low levels of CXCL10 and STAT1 mRNA were associated with poor prognosis in univariate analysis (Kaplan-Meier). MMP2 (p = .001) and extra-nodal extension (ENE) (p = .006) were independent biomarkers of disease-specific survival (DSS) in multivariate analysis and defined prognostic groups with 5-year DSS ranging from 36% (MMP2highENE+) to 88% (MMP2lowENE-). The expression of 18 G was similar in the different prognostic groups, suggesting comparable responsiveness to anti-PD-1. CONCLUSION: High levels of MMP2 were an independent and validated prognostic biomarker, surpassing other molecules of a large panel of the tumor and immune-related processes, which may be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens. Taylor & Francis 2020-05-13 /pmc/articles/PMC7466851/ /pubmed/32934875 http://dx.doi.org/10.1080/2162402X.2020.1754094 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Hoffmann, Caroline Vacher, Sophie Sirven, Philémon Lecerf, Charlotte Massenet, Lucile Moreira, Aurélie Surun, Aurore Schnitzler, Anne Klijanienko, Jerzy Mariani, Odette Jeannot, Emmanuelle Badois, Nathalie Lesnik, Maria Choussy, Olivier Le Tourneau, Christophe Guillot-Delost, Maude Kamal, Maud Bieche, Ivan Soumelis, Vassili MMP2 as an independent prognostic stratifier in oral cavity cancers |
title | MMP2 as an independent prognostic stratifier in oral cavity cancers |
title_full | MMP2 as an independent prognostic stratifier in oral cavity cancers |
title_fullStr | MMP2 as an independent prognostic stratifier in oral cavity cancers |
title_full_unstemmed | MMP2 as an independent prognostic stratifier in oral cavity cancers |
title_short | MMP2 as an independent prognostic stratifier in oral cavity cancers |
title_sort | mmp2 as an independent prognostic stratifier in oral cavity cancers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466851/ https://www.ncbi.nlm.nih.gov/pubmed/32934875 http://dx.doi.org/10.1080/2162402X.2020.1754094 |
work_keys_str_mv | AT hoffmanncaroline mmp2asanindependentprognosticstratifierinoralcavitycancers AT vachersophie mmp2asanindependentprognosticstratifierinoralcavitycancers AT sirvenphilemon mmp2asanindependentprognosticstratifierinoralcavitycancers AT lecerfcharlotte mmp2asanindependentprognosticstratifierinoralcavitycancers AT massenetlucile mmp2asanindependentprognosticstratifierinoralcavitycancers AT moreiraaurelie mmp2asanindependentprognosticstratifierinoralcavitycancers AT surunaurore mmp2asanindependentprognosticstratifierinoralcavitycancers AT schnitzleranne mmp2asanindependentprognosticstratifierinoralcavitycancers AT klijanienkojerzy mmp2asanindependentprognosticstratifierinoralcavitycancers AT marianiodette mmp2asanindependentprognosticstratifierinoralcavitycancers AT jeannotemmanuelle mmp2asanindependentprognosticstratifierinoralcavitycancers AT badoisnathalie mmp2asanindependentprognosticstratifierinoralcavitycancers AT lesnikmaria mmp2asanindependentprognosticstratifierinoralcavitycancers AT choussyolivier mmp2asanindependentprognosticstratifierinoralcavitycancers AT letourneauchristophe mmp2asanindependentprognosticstratifierinoralcavitycancers AT guillotdelostmaude mmp2asanindependentprognosticstratifierinoralcavitycancers AT kamalmaud mmp2asanindependentprognosticstratifierinoralcavitycancers AT biecheivan mmp2asanindependentprognosticstratifierinoralcavitycancers AT soumelisvassili mmp2asanindependentprognosticstratifierinoralcavitycancers |